Akers Biosciences' Q1 revenue dips

Akers Biosciences saw its revenue come in lower for the first quarter, including for its flagship PIFA Heparin PF/4 Rapid Assay products.

Total revenue for the three months to 31 March was $667,250, from $738,023. From the flagship PIFA Heparin PF/4 products it was $560,921, from $635,173 a year earlier. Sales of the flagship product had risen from the $548,068 seen in the fourth quarter.

"The positive momentum continued in Q1 2017 with domestic US sales of PIFA Heparin PF/4 Rapid Assay products up on the prior quarter by approximately 2.3%," said chief executive John Gormally.

"We are poised for growth from these products through the remainder of the year, both domestically and from renewed buying from international markets in Europe and Asia," he said.

"Our refocused sales strategy in the U.S. has resulted in a significant increase in sales per sales consultant."

At 10:22 BST, shares in AIM-listed Akers were flat at 130p each.